%0 Journal Article
%A Awwad, Mohamed H S
%A Mahmoud, Abdelrahman
%A Bruns, Heiko
%A Echchannaoui, Hakim
%A Kriegsmann, Katharina
%A Lutz, Raphael
%A Raab, Marc-Steffen
%A Bertsch, Uta
%A Munder, Markus
%A Jauch, Anna
%A Weisel, Katja
%A Maier, Bettina
%A Weinhold, Niels
%A Salwender, Hans Jürgen
%A Eckstein, Volker
%A Hänel, Mathias
%A Fenk, Roland
%A Dürig, Jan
%A Brors, Benedikt
%A Benner, Axel
%A Müller-Tidow, Carsten
%A Goldschmidt, Hartmut
%A Hundemer, Michael
%T Selective elimination of immunosuppressive T cells in patients with multiple myeloma.
%J Leukemia
%V 35
%N 9
%@ 1476-5551
%C London
%I Springer Nature
%M DKFZ-2021-00415
%P 2602-2615
%D 2021
%Z 2021 Sep;35(9):2602-2615
%X Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33597728
%R 10.1038/s41375-021-01172-x
%U https://inrepo02.dkfz.de/record/167550